Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mitsubishi Chemical Licenses SPR Technology from Quantech
February 19, 2001
- Delisting Should Be Considered for Certain Drugs: Finance Ministry Officer
February 19, 2001
- Nihon Nosan Kogyo Forms Alliance with PPL Therapeutics of UK for Genomic Technology
February 19, 2001
- Japan, EU Mutual GMP Recognition Coming Soon
February 19, 2001
- Society to Request 3-month Prescription Periods for Anti-HIV Drugs
February 19, 2001
- Price of Seroquel Is 4 Times Higher Than Lullan
February 19, 2001
- RA Patient Group Holds Survey on Clinical Trials
February 19, 2001
- Long, Short-term Goals Must Be Set for Reform: JMA President
February 19, 2001
- Asthma Telemedicine Should Reduce Asthma Deaths: Teijin Seminar
February 19, 2001
- Chugai's '75-year History' Published
February 19, 2001
- Standard Drug Name, Lab Test Masters Completed
February 19, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 19, 2001
- Locate in Scotland, Scottish Trade International Move to New Office
February 19, 2001
- Average Bungyo Rate for All Programs Exceeds 40% for First Time
February 19, 2001
- Korosho Denies Need for Further Deregulation
February 19, 2001
- Sumitomo Revises Sales for 2002 Upward to \150 Billion: President Yokotsuka
February 19, 2001
- FPMAJ Drafts GL for Distinctive Labeling of Paper, Plastic Packages
February 19, 2001
- J&J Pushes Sales of Tylenol Series
February 19, 2001
- Fujisawa Aims at Top Share in Market for Psychotropics
February 19, 2001
- Guide to Prepare NDA Dossiers According to CTD Published
February 19, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…